## **Core Concept**
HMG-CoA reductase is a key enzyme in the biosynthesis of cholesterol. It catalyzes the conversion of HMG-CoA to mevalonate, a necessary step in the hepatic production of cholesterol. Inhibitors of this enzyme are widely used to lower cholesterol levels in patients with hypercholesterolemia.

## **Why the Correct Answer is Right**
The correct answer, **Statins**, are competitive inhibitors of HMG-CoA reductase. They mimic the structure of HMG-CoA and bind to the active site of the enzyme, thereby reducing its activity. This inhibition leads to a decrease in cholesterol synthesis in the liver, which in turn increases the expression of LDL receptors on the liver cells, enhancing the clearance of LDL cholesterol from the bloodstream.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not correspond to any known class of HMG-CoA reductase inhibitors.
- **Option B:** This option is incorrect as it also does not represent a recognized inhibitor of HMG-CoA reductase.
- **Option D:** This option is incorrect because it too does not accurately describe a substance that inhibits HMG-CoA reductase.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **Statins** are among the most commonly prescribed drugs for lowering LDL cholesterol and preventing cardiovascular disease. However, they can have side effects, such as myopathy, and interactions, notably with other drugs that are metabolized by the cytochrome P450 system.

## **Correct Answer Line**
**Correct Answer: C. Statins**